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Summary 
A better understanding of the pathophysiological role of Langerhans cells (LC) in atopic diseases 
is dictated by the characterization of the structures involved in immunoglobulin (IgE)-binding 
on their cell surface. We previously reported that human LC express the high affinity receptor 
for IgE (FceRI), as well as the low affinity  receptor for IgE (FceRII/CD23).  In the present 
study, we document the presence of a third IgE-binding structure on human LC, the IgE-binding 
protein (eBP), an endogenous soluble 3-galactoside binding lectin. Immunohistochemical  studies 
performed on normal human skin revealed an anti-eBP reactivity in the cytoplasm of keratinocytes 
and in that of acinous cells of eccrine sweat glands,  eBP was also found on the cell surface of 
LC, as shown by anti-eBP/anti-CDla double labeling and flow cytometric analysis. Anti-EBP 
binding to the surface of LC was completely abolished by preincubation with lactose and restored 
by addition of recombinant human eBP, indicating that eBP binds to LC surface by virtue of 
its lectin property. Immunoblot analysis of anti-eBP-reactive material in keratinocytes and purified 
LC disclosed  a protein with an  apparent molecular weight of 33,000 consistent with eBP. 
Interestingly, mRNA transcripts for eBP were detected only in keratinocytes but not in purified 
LC isolated from normal skin. eBP was found to be released in culture supernatants of keratinocytes. 
Incubation of LC with these supernatants resulted in eBP-binding to LC surface via protein- 
carbohydrate interaction. Most importantly, we could show that binding of human myeloma 
IgE to LC was inhibited by eBP. In contrast, neuraminidase-treated human myeloma IgE binds 
to LC only in the presence of eBP. In situ binding studies revealed that keratinocytes,  although 
containing eBP intracytoplasmatically,  failed to exhibit any IgE-binding properties. Collectively, 
our results suggest that human keratinocytes produce the/J-galactoside-binding lectin eBP, which 
subsequently binds to the surface of LC where it is functional in modulating their binding capacity 
for IgE glycoforms. 
I 
gE-binding structures play a pivotal role in many patho- 
physiological mechanisms of atopic diseases. Recently, in- 
creasing attention has been drawn to antigen presenting den- 
dritic cells in the skin, the epidermal Langerhans cells (LC) 1, 
1 Abbreviations used in this paper: APAAP, alkaline phosphatase  mouse 
anti-alkaline  phosphatase;  eBP, IgE binding protein;  CM,  conditioned 
media; EC, epidermal cell; FceRI, high affinity receptor for IgE; FceRII 
low affinity receptor for IgE; GaR, goat anti-rabbit;  LC, Langerhans cell; 
Ma-h, mouse anti-human; MaR, mouse anti-rabbit;  neur, neuramidase; 
RaM, rabbit  anti-mouse; TBS, Tris-buffered saline. 
since they have been found to bind IgE molecules in situ in 
these diseases (1). Therefore we have focused our interest on 
structures involved in interactions between IgE molecules and 
LC. So far, we have demonstrated the presence of two IgE re- 
ceptors on LC: the low affinity receptor for IgE (EceRII/CD23) 
(2) and the high affinity receptor for IgE (PceRI) (3, 4), the 
latter being initially described to be exclusively found on mast 
cells and basophils (5). Beside these well-described receptors, 
a third type of IgE-binding structure has been characterized 
in the human and rodent immune systems namely, the so- 
called IgE-binding protein, eBP, which was originally de- 
777  J. Exp. Med.  @ The Rockefeller University  Press ￿9 0022-1007/93/09/0777/09  $2.00 
Volume 178  September  1993  777-785 scribed on rat basophilic leukemia cells (RBL) (6, 7). cDNA 
coding for rat and human eBP revealed that this protein was 
distinct from FceRI and FceRII (8, 9). Subsequently, it was 
demonstrated that eBP is identical to: (a) the carbohydrate 
binding  protein  35  (CBP  35)  (10,  11),  a  mouse  galac- 
rose-binding lectin found in fibroblasts; (b) Mac-2, a protein 
expressed mainly on the cell surface of murine  thioglycol- 
late-elicited peritoneal macrophages, macrophage cell lines, 
interdigitating  dendritic cells,  and also in the cytoplasm of 
some epithelial cells (12-14); and finally to (c) HL-29 or L34, 
both lectines with specificity for B-galactoside (15-17).  All 
these structures share common characteristics (18) including 
a  molecular  weight  of 29,000-35,000,  the  lack  of both 
identifiable signal peptide and transmembrane segment. The 
carbohydrate recognition domain is located in the COOH- 
terminal portion whereas the NH2-terminal portion consists 
of tandem repeats. Finally,  they are expressed by various cell 
types, and localized on the cell surface and/or in the cytoplasm 
and/or in the nucleus. The functional role of EBP is, as yet, 
poorly understood. However, some studies suggest its involve- 
ment in a growth regulation (11, 19), as a nonintegrin laminin 
binding protein (20), and most interestingly,  as an IgE-binding 
structure  (9). 
eBP/Mac-2-reactivity has been observed in murine skin (21), 
but studies of this protein in the skin of other  species  are 
still lacking. In particular,  it would be desirable to establish 
the expression and function of this IgE-binding  protein in 
human  skin,  which is the localization  and/or the target of 
many IgE-mediated allergic reactions.  Therefore, we inves- 
tigated the expression of eBP in normal human skin and ad- 
dressed the question of whether epidermal LC express this 
molecule. Furthermore, we studied the functional significance 
of eBP by analyzing its involvement in the IgE-binding ca- 
pacity of human  LC. 
Materials  and Methods 
Reagents.  Human myeloma IgE (hlgE) was purchased from Cal- 
biochem Corp.  (Bad Soden, FRG) and the FITC-labeled mouse 
anti-human-IgE  (Ma-hlgE/FITC)  antibody was obtained  from 
Nordic (Tilburg, The Netherlands). Mouse IgE anti-B-hctoglobulin 
and rabbit anti-mouse IgE (RaM-IgE) were a kind gift from Dr. 
D. Granato (Nestec Research Center, Lausanne, Switzerland). Un- 
labeled mAb IOT6a (IgG1) (Immunotech,  Marseille, France) and 
PE-labeled T6/RD1 (IgG1) (Coultertronics, Krefeld, Germany) are 
directed against CDla which,  in the skin, is present only on LC 
(22). The monospecific rabbit anti-eBP antibody and the recom- 
binant human ~BP (rheBP) have been produced as described in de- 
tail elsewhere (23-25).  Rabbit anti-mouse antibody (RaM-IgG), 
mouse  anti-rabbit  (MaR-IgG),  and  alkaline-phosphatase mouse 
anti-alkaline-phosphatase complexes (APAAP) were purchased from 
Dakopatts  (Hamburg,  Germany).  FITC-labeled goat anti-rabbit 
(GaR/FITC) obtained from Jackson ImmunoResearch  Laborato- 
ries, Inc. (West Grove, PA). Lactose, neuraminidase, NP-40, and 
normal rabbit serum were from Sigma Chemical Co. (St. Louis, 
MO). Isotype controls were from Becton Dickinson & Co. (Moun- 
tain View, CA). 
Cell Lines.  The monoblastic cell line U937 was obtained from 
the American Type Tissue Culture Collection  (Rockville, MD). 
The spontaneously transformed human keratinocyte cell line HaCaT 
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(26) was generously provided by Dr. N. Fusenig (German Cancer 
Institute,  Heidelberg,  Germany). 
In Situ Immunolabeling on Cryosections.  For studies on normal 
skin, split-thickness specimens from cadaver skin (buttocks) were 
obtained by using a handdermatome  (Weck& Co., Research Tri- 
angle, NC). For the preparation of vertical skin cryosections, 6-ram 
punch biopsies were taken from those specimens, snap-frozen in 
liquid nitrogen, and stored at -70~  6-/~m cryosections were then 
prepared,  air-dried,  fixed for 10 min in pure  acetone, and then 
processed for immunohistochemistry using the APAAP technique. 
Anti-EBP was diluted 1:500 in Tris-buffered saline (TBS) and in- 
cubated on the sections. After two washes in TBS, the sections 
were overlayed with MaK-IgG (1:20), followed, after two washes, 
by an incubation with the RaM-IgG antibody (diluted 1:10). After 
two more washes in TBS, the sections were incubated with the 
APAAP complexes (final dilution 1:10). The second and third step 
were repeated once. All incubations were performed for I h at room 
temperature.  After two washes in TBS, the substrate was added. 
This suhstrate was prepared essentially as described (27). The color 
reaction was controlled under the light microscope. After "10 rain, 
the sections were washed in distilled water and mounted in Kayser's 
gelatine  (Merck, Darmstadt,  FlkG). 
LC-enriched Epidermal Cell Suspensions.  Crude epidermal cell 
(EC) suspensions were obtained by trypsinization of split-thickness 
cadaver skin specimens as described  elsewhere  in details (2). Resulting 
cells were subjected to Lymphoprep (Nyegaard, Oslo, Norway) cen- 
trifugation.  The interface cell layer (viability >95% as determined 
by trypan blue exclusion) was then collected and the enrichment 
for LC (30-70%) was controlled by T6/RD1 immunolabeling. The 
whole procedure takes "10 h and the final cell preparation is now 
referred to as LC-enriched EC. 
Keratinocyte-conditioned Medium.  HaCaT  cells  or  collagen- 
adherent human  normal keratinocytes (HNK) were cultured  for 
38 h in DMEM supplemented with 10% FCS, 1% antibiotics/ 
antimycotics (Gibco, Essenstein, FKG), 2 mM t-glutamine (Gibco), 
25 mM Hepes buffer (Seromed, Berlin,  FRG),  5 mM sodium- 
pyruvate (Gibco) and 1% nonessential amino acids (Gibco). These 
keratinocyte-conditioned  media (HaCaT-CM or HNK-CM) were 
then collected, filtered through 0.2-/xm filters (Millipore, Eschbom, 
FKG),  concentrated,  and stored frozen at  -20~ 
Flow Cytometric Analysis.  Freshly isolated LC-enriched EC (2 
x  10  s) were washed twice in cold PBS containing 0.01% sodium 
azide and were incubated for 30 min with heat-inactivated human 
AB serum. Then cells were subjected to double labeling and flow 
cytometric analysis. LC-enriched EC were first incubated with anti- 
eBP (diluted  1:500 in PBS) for 30 rain.  After  two washes with 
cold PBS, the cells were incubated for 30 rain with GaR/FITC 
(diluted 1:500 in PBS). After another  two washes, the ceils were 
then incubated with the anti-CDla mAb T6/ILD1  (1/~g/ml)  for 
30 rain. Controls  were performed by omitting anti-eBP or using 
normal rabbit serum (diluted 1:500 in PBS). In experiments evalu- 
ating the eBP-binding capacity of various cells, suspensions were 
preincubated with rheBP at 4/zg/ml or 0.2 M lactose, respectively, 
and then stained as described above. All incubations  and washes 
were performed at 4~  Cells were then washed twice in PBS plus 
0.01% sodium azide and analyzed on a FACScan  |  (Becton Dick- 
inson & Co.). Fluorescence  parameters were collected  using a built-in 
logarithmic amplifier after gating on the combination  of forward 
light scatter and T6/RD1 labeling. Nonviable cultured cells were 
excluded by 7-amino-actinomycin-n labeling as described (28). In 
all experiments, fluorescence  data of 10,000 cells were acquired with 
logarithmic scale, the instruments set up on 256 channels, and ana- 
lyzed with Lysis II software (Becton Dickinson & Co.). All experi- 
ments were performed at least in triplicate. 
IgE-binding Protein on Langerhans Cells Western Blot Analysis.  Crude EC were isolated by trypsiniza- 
tion, and LC were first enriched by gradient density configuration 
as described above. Then, purified LC or LC-depleted EC were pre- 
pared  by using  anti-CDla  antibody  (IOT6a)  bound  to  sheep 
anti-mouse  coated  280  nm  magnetic  beads  according  to  the 
manufacturer's  protocols (Dynal,  Oslo,  Norway).  The purity of 
the LC preparation  was controlled  after each application to the 
magnet by light microscopy, and the procedure was stopped when 
unbound cells, i.e., HNK and other cells, were completely removed. 
Usually, at least 8-10 applications and washes were necessary to 
yield highly purified LC (>99%) preparation. This preparation was 
also adequate for Northern blot analysis (see below). The cells were 
washed, lysed in NP-40-containing  buffer, and 14/zg of protein 
were separated by 12% SDS-PAGE. The separated proteins were 
electroblotted onto nitrocellulose, treated with 5% dry milk, and 
then incubated for I h with anti-eBP (diluted 1:500 in PBS). Binding 
of the primary antibody was revealed  by the incubation with a MaR- 
IgG and then  a peroxidase-conjugated goat anti-mouse Ig anti- 
body (Bio-Rad Laboratories, Richmond, CA) followed by an en- 
hanced chemiluminescence Western blot detection system (ECL; 
Amersham Corp., Arlington Heights, IL) according to the manufac- 
turer's  protocol. 
Northern Blot Analysis.  Purified LC and LC-depleted EC were 
prepared as described for Western blot analysis. Total RNA was 
isolated from these cells and from eBP-negative U937 cells by stan- 
dard procedure (29) and prepared for Northern blot after transfer 
to Hybond N+ TM  membrane  (Amersham  Corp.).  EcoKI frag- 
ments of a plasmid containing  the human  eBP cDNA (9) were 
labeled with 32p with a random  primer  labeling kit (Amersham 
Corp.). Nylon membranes were prehybridized and hybridized over- 
night  according to the manufacturer's  recommendations.  Mem- 
branes  were  washed  at  room  temperature  for  30  min  in  2x 
SSC/0.5% SDS, followed by 30 min in lx  SSC/0.1% SDS. Final 
washes were performed for 30 min at 68~  in 0.2x  SSC/0.1% 
SDS. Hybridized  membranes were exposed to Kodak X-AR film 
for 24 h at  -80~ 
IgE-Binding and-Blocking Studies.  IgE-binding on EC was ana- 
lyzed in vitro on LC-enriched EC suspensions and in situ on cryosec- 
tions of normal human skin. For these experiments, both untreated 
hlgE and a desialylated form of this IgE were used. The latter was 
prepared by treatment with neuraminidase (0.2 U for 5/~g hlgE 
at 37~  for 5 h) and will be referred to as neur-hlgE.  IgE-binding 
capacity of LC-enriched EC suspensions was evaluated by first in- 
cubating  the cells with 0.2 M lactose followed by staining with 
T6/RD1 at 1 #g/ml, and two washes in PBS/0.1% sodium azide. 
Then, the cells were either incubated with rheBP and hlgE or they 
were directly incubated with either of the IgE forms without prein- 
cubation with rheBP. Finally, cells were washed once, stained with 
Ma-hlgE/FITC or FITC-labeled isotype control (both at 5/zg/ml), 
washed again,  and analyzed by flow eytometry. 
Cryosections of normal human skin were incubated for 2 h with 
either hlgE or human polyclonal IgE or routine IgE (all 30/zg/ml), 
diluted in TBS followed by Ma-hlgE antibody or a RaM-IgE anti- 
body (diluted 1:20 in TBS), respectively. After two washes in TBS, 
sections incubated with murine IgE were incubated with a mouse 
anti-rabbit Ig antibody (1:20 in TBS). Finally, all sections were 
incubated successively  with RaM-IgG, and APAAP complexes and 
the enzyme substrate as described above. 
Results 
6BP Reactivity in Normal Human Skin.  Immtmohistochem- 
ical studies revealed 6BP reactivity on various distinct  cells 
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in normal human skin. In the deep dermis, a strong and diffuse 
staining was observed in the cytoplasm, but not in the nu- 
cleus of acinous cells from eccrine sweat glands  (Fig.  1 a). 
Only rare and scattered, large and sometimes dendritic cells 
with a membranous pattern were observed in the mid and 
upper dermis.  Other cells failed to react with anti-eBP.  In 
the epidermal compartment,  two types of cells were reac- 
tive.  First, nearly all HNK were stained.  This pattern was, 
as for eccrine sweat glands, cytoplasmic and sparing the nu- 
cleus (Fig.  1 b). Second, between HNK, cells with dendritic 
shape exhibiting a membranous pattern were observed in the 
epidermis. The staining was generally weak but a more pro- 
nounced reactivity was detected on dendritic cells located in 
the  follicular  epidermis  (Fig.  1  b).  Control  staining  with 
normal rabbit serum as a first step remained negative. Simi- 
larly,  preincubation of sections with 0.2 M  lactose resulted 
in a negative anti-eBP staining of all cells. These results show 
that,  in normal human skin,  in addition to epithelial cells, 
eBP reactivity is found on epidermal  dendritic  cells. 
Surface Expression of eBP on Human LC.  Since,  in other 
cell types, eBP has been shown to be present as an intracel- 
lular and/or cell surface protein, double staining experiments 
on freshly isolated LC-enriched EC were then performed in 
order to (a) determine whether the membranous pattern ob- 
served in immunohistochemistry  is due to a surface expres- 
sion of eBP on these epidermal dendritic cells, and (b) to iden- 
tify this cell type. The staining was performed on unfixed 
cells, since fixation of EC would have potentially lead to the 
staining  of intracytoplasmic  cBP and/or  to  the  release  of 
intracellular eBP from keratinocytes with a subsequent pos- 
sible absorption/binding of eBP on EC. Thus, flow cytometric 
analysis on LC-enriched EC confirmed that a CDla-positive 
subpopulation of EC, i.e., LC, display anti-eBP reactivity (Fig. 
2 b), whereas keratinocytes were found to be hardly stained 
(Fig. 2 a). Interestingly, there was a marked difference in anti- 
eBP reactivity on LC isolated from different individuals. Hence, 
from  these  experiments  we  concluded  that,  in  human 
epidermis, eBP reactivity can be detected on cell surface of 
LC and,  to a much lesser extent,  keratinocytes. 
Biochemical Characterization of eBP in Human Epidermis.  To 
verify the specificity of the observed immunoreactivity in the 
above experiments, immunoblot analysis  was performed on 
lysates from LC-depleted EC and from purified LC. Thus, 
after SDS-PAGE separation of cell lysates from LC-depleted 
EC, the monospecific antibody recognized a single protein 
with an apparent molecular weight of about 33,000 (Fig. 3, 
lane 2).  A  similar protein  was also found on lysates from 
purified LC (Fig. 3, lane 1), whereas incubation of normal 
rabbit serum as the first step only show some few unspecific 
weak bands with higher molecular weights, most probably 
due to adsorption of serum proteins on the blot (Fig. 3, lane 
3). Lysates of U937 cells remained negative (data not shown). 
These results further established the presence of eBP in HNK 
and LC. 
eBP Is Bound Via Carbohydrates onto LC Su[face.  Since eBP 
is found as a cell surface protein but lacks a hydrophobic trans- 
membrane domain,  this implies a distinct  binding mecha- 
nism most likely involving its lectin property. To verify this Figure  1.  Presence  of anti-eBP reactivity  in skin epithelia. Cryosections  of normal human skin were incubated with anti-eBP antibody  and the 
binding revealed  by alkaline-phosphatase  mouse anti-alkaline-phosphatase  technique. (a) Reactivity  in eccrine  sweat glands  (arrows) or normal  human 
skin. (b) Reactivity  in keratinocytes  (long arrows) and dendritic cells (arrowheads) in the epidermis and dermis (short arrows). 
hypothesis on I.C, l.C-enriched EC were either left untreated 
or incubated with 0.2 M lactose or with PBS and then double 
stained with anti-eBP and anti-CDla and finally subjected 
to flow cytometric analysis. Whereas PBS-treated LC displayed 
an anti-eBP reactivity similar to untreated LC, preincuba- 
tion with lactose led to a complete disappearance of the anti- 
eBP reactivity on LC and HNK,  suggesting that 6BP has 
been eluted from the cell  surface  (Fig.  4b).  This could be 
confirmed in experiments in which the staining was restored 
by incubating the cells with rheBP after the lactose  treat- 
ment. Most importantly, when LC either untreated, treated 
with PBS, or treated with lactose were incubated with in- 
creasing concentrations (0.1-10/~g/ml) of rhEBP, the staining 
intensity was much higher than that of untreated LC, satu- 
ration being reached with 4/zg/ml rheBP (Fig. 4c). This in- 
dicated the presence of high amounts of potential eBP-binding 








Figure 2.  Analysis of ~BP expression on freshly isolated HNK (a) and 
human LC (b). Epidermal call suspensions were obtained by trypsiniza- 
tion and double labeling was performed on unfixed calls using anti-CDla 
and anti-~BP followed by flow r  analysis.  For overlay  histograms, 
HNK (a) and LC (b) were gated based on the lack or presence of CDla 
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Figure 4.  Carbohydrate-mediated eBP-hinding onto LC surface. Epi- 
dermal cell suspensions were obtained by trypsinization of normal skin 
and LC were enriched by gradient density centrifugation. Then cells were 
either directly double stained with anti-CDla and anti-eBP (a) or treated 
with 0.2 M lactose before staining (b) or treated with lactose and then 
incubated with rheBP before staining (c). For overlay  histograms, I.C were 
gated based on the presence of CDla positivity. 
Figure 3.  Immunoblot analysis of eBP on LC and HNK. Cell lysates 
from purified LC (lanes I  and 3), LC-depleted EC (lanes 2 and 4) were 
subjected to SDS-PAGE  separation, blotted to nitrocellulose, and incubated 
either with anti-eBP antibody  (lanes 1 and 2) or with normal rabbit serum 
(lanes 3 and 4) followed by peroxidase-conjugated goat anti-mouse Ig an- 
tibody and revealed by chemiluminescence. 
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sites on these cells. In contrast, only very low amounts of 
such potential eBP-binding sites were observed on HNK. From 
these experiments, we can conclude that eBP binds to LC 
surface by the virtue of its lectin property. 
Keratinocytes Are the Major Source of  6BP Found on IXT.  To 
ascertain  the origin of the eBP molecules found on I.C sur- 
face, the presence  of specific transcripts for eBP was inves- Figure  5.  Detection  of eBP mRNA 
on EC. RNA was extracted  from  cell ly- 
sates of  purified  LC (lane I), LC-depleted 
EC (lane  2), and U937 cells (lane  3) and 
subjected to agarose gel electrophoresis 
and transferred  to nylon  membrane.  Then 
they were hybridized  with EcoRI frag- 
ments of a plasmid  containing  the human 
eBP cDNA (9) which  were  labeled  with 
32p, and the membrane exposed over- 
night. 
tigated in LC-depleted EC, i.e., HNK, and in purified LC. 
Therefore, Northern blot analysis, using a specific probe for 
human eBP, was performed on total RNA isolated from ei- 
ther cell population and from U937 cells used as a control. 
As shown on Fig. 5 (lane 2), a specific signal at 1.4 kb was 
obtained from lysates of HNK, but no transcript was found 
in purified LC (Fig. 5, lane I). Hybridization of lysates from 
U937 cells remained negative (Fig. 5, lane 3). Thus, in con- 
trast to HNK, LC extracted from normal human skin fail 
to exhibit detectable eBP gene transcription. 
To verify the hypothesis that HNK release eBP, LC were 
incubated  with  HNK-CM,  stained  for  surface  anti-eBP- 
reactivity and analyzed by flow cytometry. Thereby, CM of 
both normal HNK and HaCaT cells led to an increase of the 
anti-eBP-reactivity of freshly isolated LC (Fig. 6). Similarly, 
when LC were first pretreated with lactose,  leading to the 
loss of surface-bound 6BP, the subsequent incubation with 
HNK- or HaCaT-CM restored and even enhanced the anti- 
eBP reactivity on these cells (data not shown).  Since CM 
have been obtained from subconfluent cells with >98~  via- 
bility, eBP was most probably produced by keratinocytes in 
these CM and not passively released during cell death. This 
suggests that, at least in normal skin, eBP on the LC surface 
is most likely derived from HNK. 
Human LC Bind IgE Molecules via eBP.  It has been demon- 
strated that soluble eBP binds to IgE molecules via their car- 
bohydrates (8). In a first series of experiments, the contribu- 
tion of surface 6BP to the IgE-binding capacity of LC was 
evaluated by using either untreated highly sialylated hlgE or 
low sialylated neur-hlgE. As shown on Fig. 7, whereas freshly 
isolated LC were loadable with hIgE, only a faint binding 
of neur-hIgE was detectable in the absence of exogenous eBP. 
In contrast, the addition of rh6BP (4/xg/ml) enhanced the 
binding of neur-hIgE to LC. Furthermore, when the cells 
were loaded with neur-hIgE and high concentrations of rh~BP 
(50/~g/ml), a dramatic increase in the binding was noticed. 
In contrast, preincubation of  untreated hlgE with rhEBP (50 
/zg/ml) led to a dramatic decrease in the IgE-binding capacity 
of LC. It should be noticed that, before the binding studies, 
the presence of IgE and the expression  of FcetLI on freshly 
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Figure  6.  Binding  of  keratinocyte-derived  eBP on LC. LC-enriched  EC 
were obtained  as described  in Fig. 4 and treated  with 0.2 M lactose. Then 
they  were  incubated  with  conditioned  media  of  cultured  HNK (a) or HaCat 
cells (b) and double  labeling  with anti-CDla  and anti-eBP  was performed 
as described. For overlay  histograms,  LC were  gated  based  on the presence 
of CDla positivity. 
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Figure  7.  eBP-mediated  binding  ofhypo-sialylated  IgE on LC. Freshly 
isolated LC were incubated  with PBS or various  forms  of IgE in the pres- 
ence  or absence  of  rheBP. Cells  were  then  double  stained  with anti-CDlaPE 
and Ma-hlgE, and analyzed  by flow  cytometry.  Neuraminidase  treatment 
of the Ma-hlgE (neur-Ma-hIgE) was included  as a control. The results 
are given in percent positive cells (mean _+  SEM of three independent 
experiments) relative to isotype control 
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of neur-hlgE was detectable in the absence of exogenous eBP. 
In contrast,  the addition of rheBP (4 ~g/ml) enhanced the 
binding of neur-hlgE to LC. Furthermore, when the cells 
were loaded with neur-hlgE and high concentrations of  rheBP 
(50/zg/ml), a dramatic increase in the binding was noticed. 
In contrast, preincubation of untreated hlgE with rheBP (50 
/~g/ml) led to a dramatic decrease in the IgE-binding capacity 
of LC. It should be noticed that, before the binding studies, 
the presence of IgE and the expression of FceRI on freshly 
isolated LC were first controlled by anti-IgE and anti-FcERI 
staining, respectively. Whereas no IgE was detectable on LC, 
FceRI expression was, as expected, consistently  present  in 
all experiments (data not shown). In control experiments, 
neuraminidase treatment of the anti-IgE antibody failed to 
induce any binding to eBP. 
In a second series of experiments, in situ binding studies 
on cryosections from normal human skin were designed to 
obtain further clues to the IgE-binding capacity of eBP in 
situ.  Cryosections  were either preincubated  with buffer or 
with lactose (0.2 M), followed by an incubation with hlgE 
and subsequently  stained with mAb anti-IgE.  Thereby, in 
either condition, hlgE-binding was detectable only on LC 
and not on HNK (data not shown), implying that lactose 
does not interfere with the binding site of myeloma  IgE. This 
suggests that eBP is not involved in this binding but most 
probably, FceRI is. Similar experiments were then performed 
using IgE which, in contrast to the highly sialylated hlgE, 
is constitutively low sialylated and is bound with low affinity 
to FceRI. Thereby, binding of murinelgE was clearly demon- 
strated on LC in conditions without preincubation with lac- 
tose, whereas after lactose treatment of the sections, binding 
of mlgE was hardly detectable. Interestingly, IgE-binding was 
not detected on HNK or on eccrine sweat glands although 
these cells were shown to contain eBP. From these experi- 
ments, we concluded that only cell surface eBP is able to bind 
IgE molecules. Thus, eBP contributes to the surface binding 
capacity of LC toward hyposialylated IgE species. 
Discussion 
In the present study, we report for the first time on the 
presence of the endogenous soluble lectin, IgE-binding pro- 
tein eBP, in normal human skin. This 33-kD protein was 
primarily found in high amounts in the cytoplasm of HNK 
and in eccrine sweat glands cells. The former were shown 
to represent the source of eBP found on the cell surface of 
epidermal LC, where eBP attaches to carbohydrates by virtue 
of its lectin property. Most importantly, eBP present on LC 
conferred on them the possibility to enhance their IgE-binding 
ability by selectively binding hyposialylated IgE. 
In mice, eBP was shown to be quite ubiquitously local- 
ized (30). Although highly homologous lectins of the S-type 
family such as HL-29  have been reported in several tissues 
in humans (16), reports on human eBP were still missing. 
Our observation that HNK represent a source for the fl-galac- 
toside binding soluble lectin eBP sheds a new light on the 
biology of these cells and on eBP itself in the human system 
as well. We found eBP mainly in the cytoplasm of HNK, 
but it could be recovered from culture supernatants of viable 
cells, thereby demonstrating that they are releasing this lectin. 
Similar to other soluble lectins and a number of secreted pro- 
teins such as IL-1 and fibroblast growth factor (31, 32), eBP 
lacks a classical signal peptide or transmembrane domain (13) 
and is therefore transported to the cell surface by mechanisms 
that remain to be elucidated.  As it has been reported for 
eBP/Mac-2 expression in mouse peritoneal macrophages (12), 
it is not excluded that mediators present in an inflammatory 
environment may induce LC to synthesize and secrete 6BP 
themselves. Moreover, such mediators could stimulate HNK 
to release high amounts ofeBP to the epidermal intercellular 
space. Thus, with regard to the skin surface (,'ol.7 m2), one 
may speculate the amounts of eBP molecules that could be 
released  by the epidermis under appropriate stimulation, such 
as in widespread skin diseases or sunburn dermatitis. Whether 
the released eBP would be found systemically remains to be 
clarified, but there is clear evidence that proteins of similar 
or much higher molecular weights such as immunoglobu- 
lins can have access from the circulation to the epidermis and 
vice versa. 
We have shown that keratinocyte-derived EBP binds to LC 
surface via carbohydrates. This was conclued from the fact 
that eBP could be eluted with lactose from the surface of 
freshly isolated LC.  Incubation of lactose-treated LC with 
HNK-CM led to a reconstitution of the anti-eBP reactivity 
of the cells. Interestingly, however, when freshly isolated LC 
were incubated  with increasing  concentrations  (up  to  10 
#g/ml) of recombinant human eBP, a dramatic increase of 
the eBP-binding  on LC was observed and saturation  was 
reached at 4/zg/ml. Hence, LC most likely express abundant 
potential binding sites for eBP which are far from being all 
occupied on freshly isolated LC. It is known that this lectin 
specifically binds to terminal ~-galactose residues found in 
complex type N-linked oligosaccharide chains (33). There- 
fore only glycoproteins undergoing distinct posttranslational 
processing leading to this particular glycosylation pattern rep- 
resent putative candidates as joining structures of eBP on the 
cell surface. Studies are now in progress for identifying these 
glycoproteins  on LC. 
Our results provide for the first time evidence for an eBP- 
mediated modulation of the IgE-binding capacity of LC. 
Significantly, a dichotomy in the function of eBP was ob- 
served: whereas eBP mediates  binding of neuraminidase-treated 
myeloma IgE to LC, it inhibits the binding of untreated IgE. 
The results suggest that the function of eBP depends on the 
sialylation state of the IgE molecules. Previously, it was found 
that human eBP binds rodent IgE but not human myeloma 
IgE molecules, unless the latter have been pretreated  with 
neuraminidase, thereby removing sialic acid residues from the 
oligosaccharide side chains (9). The observation that human 
eBP binds subpopulations of human polyclonal IgE (34) sup- 
ports the concept that human IgE molecules are quite heter- 
ogeneous in terms of sialylation. The results presented herein 
can be best understood in the context of differential recogni- 
tion of IgE glycoforms by eBP. 
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IgE to LC via eBP are noteworthy. IgE binding is observed 
in the presence of exogenous eBP at relatively high concen- 
trations.  Indeed, whereas maximal loading of the lectin on 
LC surface was reached with eBP concentration of 4 gg/ml, 
an increased binding of IgE through the lectin was observed 
with concentrations up to 50 gg/ml eBP. This is in line with 
a very recent demonstration that eBP molecules are monova- 
lent in terms of galactose binding sites, but that they appar- 
ently form oligomers or polymers when high concentrations 
of eBP are used (25).  Although it remains to be verified,  it 
is conceivable that such high concentrations of keratinocyte- 
derived eBP are locally reached in the narrow epidermal in- 
tercellular space. Hence, we postulate that, under these con- 
ditions,  hyposialylated human  IgE glycoforms are bridged 
to yet-to-be-defined LC  surface glycoproteins via eBP-oli- 
gomers. 
The observation that eBP inhibits the binding of human 
myeloma IgE untreated with neuraminidase  is intriguing. Since 
eBP binds untreated  human  myeloma IgE poorly,  the ob- 
served inhibitory effect is likely not due to eBP binding to 
IgE. Rather, the results may be explained by binding to FceRI 
and thereby exerting  a steric hindrance  for IgE binding  to 
FceRI.  It is to be noted that,  recently,  eBP was found to 
bind to FceRI on rodent mast cells, in addition to binding 
to IgE (Frigeri,  L.,  K.  Zuberi,  and F.-T.  Liu,  manuscript 
in preparation). Therefore, it is quite possible that eBP binds 
FceKI on LC. 
The findings that neuraminidase  treatment  of IgE led to 
a decrease in its binding  to LC also remains intriguing.  It 
has been reported that removal of sialic acid from RBL cell 
surface resulted in an increase in the association constant of 
IgE binding to these cells (35). To our knowledge, no studies 
have been conducted to test the effect of desialylation of IgE 
on the binding of IgE to FceKI or FceKII. The removal of 
negatively charged sialic acid residues from human IgE may 
lead to conformational  changes that  are detrimental  to its 
binding to FceRI. Regardless of the explanation, the findings 
again underscore the differential behaviors of IgE glycoforms 
in either direct binding  or eBP-mediated binding  to LC. 
Very recently, eBP has been implicated in the IgE binding 
to neutrophils and IgE-mediated activation of these cells (36). 
In that case too, preferential binding of neuraminidase-treated, 
desialylated IgE was noted. A picture is emerging that eBP 
is another IgE-binding structure on various cell types. The 
observations also highlight  the functional variability of var- 
ious IgE-glycoforms as a result of selectivity of eBP for dis- 
tinct  hyposialylated IgE molecules. 
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